介入术后冠脉无复流的危险因素识别与药物治疗(3)
[3]Poon K，Seth M，Dixon S，et al.The clinical implications and predictors of no reflow phenomenon in contemporary PCI：Insights from blue cross blue shield of Michigan cardiovascular collaborative Bmc2[J].J Am Coll Cardiol，2013，61(10)：e133.
[4]Soeda T，Higuma T，Abe N，et al.Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture[J].European Heart Journal Cardiovascular Imaging，2017，18(1)：103-110.
, 百拇医药
[5]Gibson CM，Schomig A.Coronary and myocardial angiography：angiographic assessment of both epicardial and myocardial perfusion[J].Circulation，2004，109(25)：3096-3105.
[6]Gavin JB，Maxwell L，Edgar SG.Microvascular involvement in cardiac pathology[J].J Mol Cell Cardiol，1998(30)：2531-2540.
[7]Klein LW，Kern MJ，Berger P，et al.Society of cardiac angiography and interventions：suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory[J].Catheter Cardiovasc Interv，2003，60(2)：194-201.
, 百拇医药
[8]Zhao S，Qi G，Tian W，et al.Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention：a meta-analysis[J].J Interv Cardiol，2014，27(4)：356-364.
[9]Su Q，Li L，Naing KA，et al.Safety and effectiveness of nitroprusside in preventing no-reflow during percutaneous coronary intervention： a systematic review[J].Cell Biochem Biophys，2014， 68(1)：201-206.
[10]Xing K，Fu X，Jiang L，et al.Cardioprotective Effect of Anisodamine Against Myocardial Ischemia Injury and its Influence on Cardiomyocytes Apoptosis[J].Cell Biochemistry & Biophysics，2015，73(3)：707-716.
, 百拇医药
[11]Niu X，Zhang J，Bai M，et al.Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction：a network meta-analysis[J].BMC Cardiovasc Disord，2018，18(1)：3.
[12]Bai S，Fu X，Gu X，et al.Intracoronary administration of different doses of anisodamine in primary percutaneous coronary intervention：protective effect in patients with ST-segment elevation myocardial infarction[J].Coronary Artery Disease，2016，27(4)：302-310.
, 百拇医药
[13]Niccoli G，Rigattieri S，De Vita MR，et al.Open-label，randomized，placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction：the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction)[J].JACC Cardiovasc Interv，2013，6(6)：580-589., 百拇医药(杨国锋 钱朝庆 白文伟)
[4]Soeda T，Higuma T，Abe N，et al.Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture[J].European Heart Journal Cardiovascular Imaging，2017，18(1)：103-110.
, 百拇医药
[5]Gibson CM，Schomig A.Coronary and myocardial angiography：angiographic assessment of both epicardial and myocardial perfusion[J].Circulation，2004，109(25)：3096-3105.
[6]Gavin JB，Maxwell L，Edgar SG.Microvascular involvement in cardiac pathology[J].J Mol Cell Cardiol，1998(30)：2531-2540.
[7]Klein LW，Kern MJ，Berger P，et al.Society of cardiac angiography and interventions：suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory[J].Catheter Cardiovasc Interv，2003，60(2)：194-201.
, 百拇医药
[8]Zhao S，Qi G，Tian W，et al.Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention：a meta-analysis[J].J Interv Cardiol，2014，27(4)：356-364.
[9]Su Q，Li L，Naing KA，et al.Safety and effectiveness of nitroprusside in preventing no-reflow during percutaneous coronary intervention： a systematic review[J].Cell Biochem Biophys，2014， 68(1)：201-206.
[10]Xing K，Fu X，Jiang L，et al.Cardioprotective Effect of Anisodamine Against Myocardial Ischemia Injury and its Influence on Cardiomyocytes Apoptosis[J].Cell Biochemistry & Biophysics，2015，73(3)：707-716.
, 百拇医药
[11]Niu X，Zhang J，Bai M，et al.Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction：a network meta-analysis[J].BMC Cardiovasc Disord，2018，18(1)：3.
[12]Bai S，Fu X，Gu X，et al.Intracoronary administration of different doses of anisodamine in primary percutaneous coronary intervention：protective effect in patients with ST-segment elevation myocardial infarction[J].Coronary Artery Disease，2016，27(4)：302-310.
, 百拇医药
[13]Niccoli G，Rigattieri S，De Vita MR，et al.Open-label，randomized，placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction：the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction)[J].JACC Cardiovasc Interv，2013，6(6)：580-589., 百拇医药(杨国锋 钱朝庆 白文伟)